PRISMMEDI
Prism Medico and Pharmacy financials
- Market cap
- ₹39 Cr
Quarterly results
Q3 FY20: revenue down 43.1%, net profit down 126.7% against the same quarter last year.
| Line item | Q4 FY18 | Q1 FY19 | Q2 FY19 | Q3 FY19 | Q4 FY19 | Q1 FY20 | Q2 FY20 | Q3 FY20 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 6 | 15 | 17 | 17 +4567% | 9 +51% | 7 −56% | 10 −43% |
| Net profit | -0 | 0 | 0 | 0 | -1 −74% | 0 −65% | 0 −68% | -0 −127% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +81.2% 1Y
1Y: ₹16.45 on 9 Sept 2025 → ₹29.81. High ₹33.9 (27 Apr 2026), low ₹16.03 (28 Jan 2026).
Financials, as filed
Revenue grew 140.1% a year over 1 year, FY18 to FY19.
| Year ending | FY18 | FY19 |
|---|---|---|
| Revenue | ₹23 Cr | ₹55 Cr |
| Interest | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹0 Cr | ₹0 Cr |
| Net profit | ₹0 Cr | ₹0 Cr |
| Net margin | 0.0% | 0.1% |
| Cash from operations | ₹4 Cr | ₹-0 Cr |
| Free cash flow | ₹4 Cr | ₹-0 Cr |
| ROE | -0.2% | 1.1% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY17 | FY18 | FY19 |
|---|---|---|---|
| Equity capital | ₹6 Cr | ₹6 Cr | ₹6 Cr |
| Reserves | ₹7 Cr | ₹7 Cr | ₹7 Cr |
| Borrowings | ₹4 Cr | ₹2 Cr | ₹0 Cr |
| Other liabilities | ₹1 Cr | ₹1 Cr | ₹12 Cr |
| Total liabilities | ₹17 Cr | ₹16 Cr | ₹25 Cr |
| Fixed assets | ₹10 Cr | ₹9 Cr | ₹9 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹3 Cr | ₹1 Cr |
| Other assets | ₹7 Cr | ₹4 Cr | ₹15 Cr |
| Total assets | ₹17 Cr | ₹16 Cr | ₹25 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters added +4.98 pp while the public trimmed −4.98 pp. The shareholder count shrank 3% to 4,177.
- Promoters
- 30.0%
- Public
- 70.0%
Since Jun 2025
- Promoters +4.98 pp
- Public −4.98 pp
How it drifted, 12 quarters
Over this window the public fell from 75.0% to 70.0% — −5.0 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 25.0%, Public 75.0%.Dec '23: Promoters 25.0%, Public 75.0%.Mar '24: Promoters 25.0%, Public 75.0%.Jun '24: Promoters 25.0%, Public 75.0%.Sep '24: Promoters 25.0%, Public 75.0%.Dec '24: Promoters 25.0%, Public 75.0%.Mar '25: Promoters 25.0%, Public 75.0%.Jun '25: Promoters 25.0%, Public 75.0%.Sep '25: Promoters 25.0%, Public 75.0%.Dec '25: Promoters 25.0%, Public 75.0%.Mar '26: Promoters 25.5%, Public 74.5%.Jun '26: Promoters 30.0%, Public 70.0%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Dharmender Kharb newly disclosed 19.35% held
- Raju Tyagi newly disclosed 9.77% held
- Galaxy Vitacare Private Limited +4.63 pp 13.25% held
- Sejal S Nashatar newly disclosed 2.51% held
- Harsh Jentibhai Rupareliya newly disclosed 2.43% held
- Shilpa Harsh Rupareliya newly disclosed 2.43% held
- Symbiosis Pharmaceuticals Private Limited +1.66 pp 15.65% held
The same filing shows 5 holders trimming and 4 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Prism Medico and Pharmacy Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Dharmender Kharb | 19.35% | newly disclosed |
| Symbiosis Pharmaceuticals Private Limited | 15.65% | +1.66 pp |
| Galaxy Vitacare Private Limited | 13.25% | +4.63 pp |
| Raju Tyagi | 9.77% | newly disclosed |
| Sejal S Nashatar | 2.51% | newly disclosed |
| Harsh Jentibhai Rupareliya | 2.43% | newly disclosed |
| Shilpa Harsh Rupareliya | 2.43% | newly disclosed |
| Anshul Jajoo | 1.40% | −0.71 pp |
| Bosco Armando Menezes | 1.11% | −1.36 pp |
| Emily Bosco Menezes | 1.11% | −1.36 pp |
| Ramit Walia | 1.07% | −1.32 pp |
| Reeta Devi | 1.03% | −1.27 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Prism Medico and Pharmacy Ltd.
Guides on how to read this kind of business and the numbers that matter.